Access to capital and funding environment for clinical-stage biopharmaceutical companies, influenced by global economic challenges and interest rates.

Investor risk appetite for speculative biotech stocks, which can be sensitive to overall market sentiment and geopolitical instability.

Clinical trial progress and regulatory outcomes for its boron-based therapeutics, crucial for a company with multiple drug candidates in development.